You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Suppliers and packagers for SULFAMETHOXAZOLE AND TRIMETHOPRIM


✉ Email this page to a colleague

« Back to Dashboard


SULFAMETHOXAZOLE AND TRIMETHOPRIM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Somerset SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 212231 ANDA Somerset Therapeutics, LLC 70069-361-10 10 VIAL in 1 CARTON (70069-361-10) / 5 mL in 1 VIAL (70069-361-01) 2019-08-29
Somerset SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 212231 ANDA Somerset Therapeutics, LLC 70069-362-10 10 VIAL in 1 CARTON (70069-362-10) / 10 mL in 1 VIAL (70069-362-01) 2019-08-29
Somerset SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 212231 ANDA Somerset Therapeutics, LLC 70069-363-01 1 VIAL in 1 CARTON (70069-363-01) / 30 mL in 1 VIAL 2019-08-29
Teva Pharms Usa SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 073303 ANDA Teva Parenteral Medicines, Inc. 0703-9503-03 10 VIAL, SINGLE-DOSE in 1 CARTON (0703-9503-03) / 5 mL in 1 VIAL, SINGLE-DOSE (0703-9503-01) 1991-11-01
Teva Pharms Usa SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 073303 ANDA Teva Parenteral Medicines, Inc. 0703-9514-83 10 VIAL, MULTI-DOSE in 1 CARTON (0703-9514-83) / 10 mL in 1 VIAL, MULTI-DOSE (0703-9514-81) 2024-07-11
Teva Pharms Usa SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 073303 ANDA Teva Parenteral Medicines, Inc. 0703-9514-03 10 VIAL, MULTI-DOSE in 1 CARTON (0703-9514-03) / 10 mL in 1 VIAL, MULTI-DOSE (0703-9514-01) 2024-07-11
Teva Pharms Usa SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim INJECTABLE;INJECTION 073303 ANDA Teva Parenteral Medicines, Inc. 0703-9514-93 10 VIAL, MULTI-DOSE in 1 CARTON (0703-9514-93) / 10 mL in 1 VIAL, MULTI-DOSE (0703-9514-91) 2024-07-11
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for Sulfamethoxazole and Trimethoprim

Last updated: February 20, 2026

Which companies manufacture Sulfamethoxazole and Trimethoprim?

Sulfamethoxazole and Trimethoprim are widely used antibiotics often combined in formulations such as Bactrim or Septra. Multiple pharmaceutical companies supply these compounds through bulk active pharmaceutical ingredients (API) and finished dosage forms.

Major API Suppliers

Company Location Certifications Notes
Mylan India, USA cGMP, ISO 9001 Supplies APIs and finished products globally.
Wockhardt India cGMP, ISO Produces Sulfamethoxazole and Trimethoprim APIs at large scale.
Aurobindo Pharma India cGMP Known for cost-effective APIs for global markets.
Hikma Pharmaceuticals UK cGMP Supplies APIs and finished medicines to Europe and other regions.
Sun Pharmaceutical India cGMP Produces APIs used in generic formulations.
Zhejiang Hisun Pharmaceutical China GMP Supplies Sulfamethoxazole API for Asian and emerging markets.

Finished Dosage Form Manufacturers

Company Notes
Teva Pharmaceuticals Global leader with marketed formulations containing Sulfamethoxazole and Trimethoprim.
Sandoz Produces generic versions for North American and European markets.
Lupin Offers both APIs and finished products, mainly for India and emerging markets.
Cipla Wide distribution of Sulfamethoxazole/Trimethoprim formulations.

Market Trends and Supply Chain Dynamics

  • API Supply Concentration: The API manufacturing landscape is concentrated in India and China, accounting for over 70% of global API production [1].
  • Regulatory Compliance: Suppliers maintaining cGMP, ISO standards are preferred for global distribution.
  • Pricing: API prices have decreased due to increased competition, influencing formulation costs.
  • Supply Risks: Dependence on API suppliers from Asia presents risks linked to geopolitical tensions and supply chain disruptions.

Regulatory Considerations

  • Certificate of Analysis (CoA): Critical for verifying API purity and compliance.
  • GMP Certification: Required for suppliers exporting to regulated markets.
  • Patent Status: Many formulations are off-patent, facilitating generic entry globally.

Key Takeaways

  • The primary active ingredients are supplied predominantly by Indian and Chinese manufacturers.
  • Major pharmaceutical companies integrate these APIs into marketed generic and branded formulations.
  • Industry is moving towards increased transparency, quality assurance, and diversification of supply sources.
  • Regulatory compliance (GMP, ISO) is essential for global distribution.
  • Supply chain vulnerabilities persist due to concentration in specific regions.

FAQs

1. Are there any exclusive suppliers for Sulfamethoxazole and Trimethoprim?
No. Multiple generic manufacturers produce these APIs, resulting in a diversified supply chain.

2. What are the main regions supplying Sulfamethoxazole and Trimethoprim APIs?
India and China are the dominant regions, accounting for most API manufacturing.

3. How do regulatory standards impact suppliers?
Suppliers must adhere to cGMP and ISO standards to export APIs to regulated markets such as the USA, EU, and Japan.

4. What are the risks in sourcing from Asian API manufacturers?
Supply disruptions caused by geopolitical issues, tariffs, or manufacturing delays can impact availability.

5. What should companies consider when choosing a supplier?
Quality certifications, manufacturing capacity, regulatory compliance, and supply reliability are crucial factors.


References

[1] Berman, M. et al. (2022). Global Active Pharmaceutical Ingredient Manufacturing Trends. International Journal of Pharmaceutical Manufacturing.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.